A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
Status:
Completed
Trial end date:
2018-10-12
Target enrollment:
Participant gender:
Summary
This is a Phase 2 randomized study with two treatment arms to compare the effectiveness of
oregovomab (a murine monoclonal antibody directed against cancer antigen 125 (CA125)) when
combined with first-line chemotherapy (carboplatin and paclitaxel) to first-line chemotherapy
(carboplatin and paclitaxel alone) in female patients with advanced ovarian cancer.